View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
October 25, 2019updated 12 Jul 2022 12:23pm

Replimune launches Phase I trial of RP2 in cancer patients

Replimune has initiated a Phase I clinical trial of its investigational candidate, RP2, as a monotherapy or in combination with Opdivo for the treatment of advanced solid tumours.

Replimune has initiated a Phase I clinical trial of its investigational candidate, RP2, as a monotherapy or in combination with Opdivo for the treatment of advanced solid tumours.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Based on the company’s Immulytic platform, RP2 expresses a genetically encoded protein that is similar to the anti-CTLA-4 antibody, along with the GALV-GP-R- fusogenic protein and GM-CSF.

The drug candidate is intended to prevent the inhibition of immune responses triggered by CTLA-4.

In preclinical studies, RP2 showed improved efficacy alone and in combination with anti-PD1 therapy.

Replimune co-founder, president and CEO Robert Coffin said: “CTLA-4 inhibition is an established mechanism of action for cancer treatment, including proven synergy with anti-PD1 therapy.

“By combining the expression of anti-CTLA-4 with oncolytic tumour destruction and antigen release directly in the tumour and draining lymph nodes, we believe that the efficacy of CTLA-4 inhibition can be enhanced with RP2, while reducing toxicity as compared to systemic administration.”

The Phase I trial will evaluate the safety and tolerability of RP2 alone and in combination with Opdivo, an anti-PD1 therapy developed by Bristol-Myers Squibb (BMS).

It also aims to determine the optimal dose. The first patient for the trial has been enrolled.

Replimune partnered with BMS for the study. BMS provided a non-exclusive, non-transferable, royalty-free licence to Opdivo for use with RP2 and will also supply its drug free of charge.

Earlier this month, Replimune started patient enrolment in a Phase II trial of another Immulytic product candidate RP1 to treat cutaneous squamous cell carcinoma (CSCC).

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena